Cipla Ltd.
CIPLA · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,062.25.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%11.7%
- ✓Low debt (D/E < 0.5)0.02x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-2%
- ✕Earnings growing-55%
- ✓Net margin ≥ 10%13.9%
- ✓Current ratio > 1.53.44
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 10.47
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 10.47.
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (3/9).
Opportunities
- •Trading in our value buy zone versus sector peers.
Threats
- •Earnings contracting year on year.
About Cipla Ltd.
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obe
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.